EA200601687A1 - Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 - Google Patents

Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1

Info

Publication number
EA200601687A1
EA200601687A1 EA200601687A EA200601687A EA200601687A1 EA 200601687 A1 EA200601687 A1 EA 200601687A1 EA 200601687 A EA200601687 A EA 200601687A EA 200601687 A EA200601687 A EA 200601687A EA 200601687 A1 EA200601687 A1 EA 200601687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igf
receptor
expression
tetragidrobenzazepinovye
tetrahydroisoquinoline
Prior art date
Application number
EA200601687A
Other languages
English (en)
Inventor
Ян Гунцингер
Курт Леандер
Original Assignee
Аналитикон С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аналитикон С.А. filed Critical Аналитикон С.А.
Publication of EA200601687A1 publication Critical patent/EA200601687A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Синтезированы соединения формулы (I), в которой R, R, Rимеют значения, как приведено в описании, и U, V и W, соответственно, могут представлять собой CR', CR' и CR', (с определениями R', R' и R' снова, как в описании) или могут означать N. Показано, что они понижающим образом регулируют или ингибируют экспрессию или функцию рецептора IGF-1.
EA200601687A 2004-03-12 2004-03-12 Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 EA200601687A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2004/000147 WO2005087743A1 (en) 2004-03-12 2004-03-12 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
EA200601687A1 true EA200601687A1 (ru) 2007-04-27

Family

ID=34957074

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601687A EA200601687A1 (ru) 2004-03-12 2004-03-12 Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1

Country Status (21)

Country Link
US (1) US7875631B2 (ru)
EP (1) EP1732898B1 (ru)
JP (1) JP2007528877A (ru)
CN (1) CN100590118C (ru)
AR (1) AR049323A1 (ru)
AT (1) ATE384700T1 (ru)
AU (1) AU2004317166B2 (ru)
BR (1) BRPI0418462A (ru)
CA (1) CA2555745C (ru)
DE (1) DE602004011578T2 (ru)
DK (1) DK1732898T3 (ru)
EA (1) EA200601687A1 (ru)
ES (1) ES2299825T3 (ru)
IL (1) IL177307A (ru)
NO (1) NO20063794L (ru)
PL (1) PL1732898T3 (ru)
PT (1) PT1732898E (ru)
SI (1) SI1732898T1 (ru)
TW (1) TW200530213A (ru)
WO (1) WO2005087743A1 (ru)
ZA (1) ZA200607198B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006288846B2 (en) * 2005-09-09 2011-08-18 Analytecon Sa Isoquinolines as IGF-1R inhibitors
EA200800786A1 (ru) * 2005-09-09 2008-08-29 Аналитикон С.А. Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем
WO2009073203A1 (en) 2007-12-04 2009-06-11 Amgen Inc. Trp-m8 receptor ligands and their use in treatments
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
ES2553871T3 (es) * 2010-07-05 2015-12-14 Actelion Pharmaceuticals Ltd. Derivados heterociclilo 1-fenil-sustituidos y su uso como moduladores del receptor D2 de prostaglandina
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
KR20150027827A (ko) 2012-07-05 2015-03-12 액테리온 파마슈티칼 리미티드 1-페닐-치환된 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN112500345B (zh) * 2020-12-18 2022-06-21 西安石油大学 α-氰基季碳取代四氢异喹啉化合物的合成方法
WO2024067463A1 (zh) * 2022-09-27 2024-04-04 苏州阿尔脉生物科技有限公司 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA1330560C (en) * 1986-05-21 1994-07-05 Maurits E. A. Vandewalle Di- and tetrahydroisoquinoline derivatives
WO1990002119A1 (en) * 1988-08-18 1990-03-08 Banyu Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AU2002222853A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic compounds
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor

Also Published As

Publication number Publication date
CN100590118C (zh) 2010-02-17
EP1732898B1 (en) 2008-01-23
US20070129399A1 (en) 2007-06-07
DE602004011578T2 (de) 2009-02-19
SI1732898T1 (sl) 2008-06-30
NO20063794L (no) 2006-12-12
CA2555745C (en) 2011-05-31
DE602004011578D1 (de) 2008-03-13
TW200530213A (en) 2005-09-16
EP1732898A1 (en) 2006-12-20
IL177307A (en) 2011-09-27
US7875631B2 (en) 2011-01-25
WO2005087743A1 (en) 2005-09-22
CN1922147A (zh) 2007-02-28
ZA200607198B (en) 2008-04-30
IL177307A0 (en) 2006-12-10
JP2007528877A (ja) 2007-10-18
AU2004317166A1 (en) 2005-09-22
PT1732898E (pt) 2008-04-07
AU2004317166B2 (en) 2010-11-11
DK1732898T3 (da) 2008-05-13
ES2299825T3 (es) 2008-06-01
CA2555745A1 (en) 2005-09-22
ATE384700T1 (de) 2008-02-15
AR049323A1 (es) 2006-07-19
BRPI0418462A (pt) 2007-06-05
PL1732898T3 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
GEP20125565B (en) Lactam compounds and their pharmaceutical use
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
BRPI0406801A (pt) Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas